The COVID-19 pandemic has raised questions about the management of people with inflammatory bowel disease (IBD). To date, there have been over 43 million confirmed cases of COVID-19 globally, including over 1.1 million deaths (https://COVID-19.who.int). What have we learnt about the risks of SARS-CoV-2 infection in patients with IBD and is there any evidence to support a change in IBD management?


This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Cite as

Lees, C., Irving, P. & Beaugerie, L. 2020, 'COVID-19 and IBD drugs: should we change anything at the moment?', Gut, 70(4), pp. 632-634. https://doi.org/10.1136/gutjnl-2020-323247

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 17 June 2022
Was this page helpful?